• Home
  • MyECTS
  • Become a member
  • Contact us

Ectsoc

Ecstoc.org

MENUMENU
  • About
    • Mission & Vision
    • Governance & Transparency
    • Board of Directors
    • Annual General Meeting
    • Committees and Action Groups
      • Executive Committee
      • Communications Committee
      • Community Engagement Committee
      • ECTS Academy
      • Education Committee
      • Clinical Science Committee
      • Research Committee
      • Scientific Programme Committee 2025
    • ECTS Team
    • Membership
      • Individual Membership
      • Corporate Supporters
      • Join us
      • Affiliated Societies
  • ECTS 2025
  • Events
    • Upcoming Congresses
    • Past Congress
    • ECTS Academy Charity Event
    • ICCBH
    • Events
  • Grants & Awards
  • Education
    • PhD Training Course
    • Clinical Training Course in Metabolic Bone Diseases
    • Rare Bone Diseases Webinars
    • Education Resource Center
    • Bone Muscle & Beyond Webinars
    • ECTS-Mellanby Training Course
    • Calendar ECTS Educational Events
  • ECTS Academy
    • About the ECTS Academy
    • ECTS Academy – Members
    • Call for Applications - Basic Scientists
    • Call for Applications - Clinicians
    • ECTS Academy Activities
      • NI Conference Program
      • ECTS Academy Webinar Series
      • ECTS Academy Mentoring Options
      • ECTS Academy Charity Run
    • Visit the ECTS Academy website
  • News
    • ECTS Newsletter
    • News
    • Press Release
    • Image Library
    • Video Library
    • Job Advertisements
You are here: Home / New investigators / Newsletter / Fracture risk in patients with rheumatoid arthritis treated with glucocorticoids and proton pump inhibitors. By Barbara Hauser

Fracture risk in patients with rheumatoid arthritis treated with glucocorticoids and proton pump inhibitors. By Barbara Hauser

Rheumatoid Arthritis (RA) is a chronic inflammatory disease with an increased risk of osteoporosis which is partly due to the disease itself and partly due to medication, in particular glucocorticoids (GC). About one quarter of RA patients are prescribed oral glucocorticoids which increases the fracture risk substantially. Proton pump inhibitors (PPI) are frequently co-prescribed in order to prevent gastrointestinal side effects of GC or Non-steroidal anti-inflammatory medications. PPI use has been associated to a possible increased fracture risk, however the magnitude and underlying mechanism of PPIs on fracture risk are not well understood.

A retrospective cohort study by Abtahi et al. included RA patients over 50 years of age who were included in the UK Clinical Practice database over a 20 years time frame. GC and PPI intake was stratified into current, recent or past use. Time-dependent Cox proportional-hazards models allowed to estimate the risk of an osteoporotic fracture in RA patients with concomitant current use of oral GCs and PPIs versus non-use.

Amongst the 12 351 RA patients, 1411 osteoporotic fractures occurred. Concomitant use of oral GC and PPI was associated with a 1.6 fold increased fracture risk compared with non-use of both drugs. Patients with either GC or PPI use alone were associated with a 1.2 fold higher fracture risk which was significantly lower than that of the combination treatment. PPI dose or duration did not seem to influence fracture risk. Interestingly, past use (> 6 months) of either GC or PPI was not associated with an increase in fracture risk confirming some aspects of reversibility in medication associated fracture risk.  The authors conclude that the combination treatment of GC and PPI may significantly increase the fracture risk in RA patients and thus such patients should be considered for a fracture risk assessment.

READ THE ARTICLE 

Join ECTS or Renew your membership today!

Discount on annual congresses, exclusive advantages, training courses and so much more

Join or renew
Tweet
Copyright 2016 ECTS - Disclaimer - Cookies Policy - Privacy Policy - Privacy Centre - Terms of use - Contact us